Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Brings extensive experience in all phases of oncology drug developmentHANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals,...

Related Keywords

San Diego ,California ,United States ,Stanford University ,Patrick Lin ,Processa Ngcs ,Lyvonne Briggs ,Steven Cha ,Stanford University School Of Medicine ,Nasdaq ,Processa Team ,Company Contact ,Pharmaceuticals Inc ,Pfizer ,Clinical Research ,Processa Pharmaceuticals Inc ,Processa Pharmaceuticals ,Tufts University School Of Medicine ,University Of California ,Senior Vice President ,Chief Executive Officer ,Cap Phase ,Puma Biotechnology ,Stanford University School ,Cell Biology ,Medical Degree ,Tufts University School ,Processa Regulatory Science Approach ,Optimal Dosage Regimens ,Regulatory Science Approach ,Optimal Dosage Regimen ,Optimus Oncology ,Next Generation Capecitabine ,Next Generation Gemcitabine ,Next Generation Irinotecan ,Relations Contact ,